17:57 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

BioCardia's CardiAMP non-significantly improves 6MWD in roll-in cohort of Phase III for heart failure

BioCardia Inc. (OTCQX:BCDA) reported data from the 10-patient roll-in cohort of the Phase III CardiAMP Heart Failure trial to treat heart failure following a heart attack showing that CardiAMP non-significantly improved mean 6-minute walk distance...
00:18 , Nov 9, 2017 |  BC Extra  |  Company News

Management tracks: Pfizer, Hansa

Pfizer Inc. (NYSE:PFE) hired Amrit Ray as global president of Pfizer essential health, R&D, effective Friday. He was SVP of external affairs at Johnson & Johnson (NYSE:JNJ). In his new role, Ray will be responsible...
22:19 , Jan 4, 2017 |  BC Week In Review  |  Clinical News

CardiAMP: Ph III CardiAMP Heart Failure started

BioCardia began the double-blind, sham-controlled, U.S. Phase III CardiAMP Heart Failure trial to evaluate CardiAMP in up to 260 patients. BioCardia Inc. (Pink:BCDA), San Carlos, Calif.  Product: CardiAMP   Business: Cardiovascular  Molecular target: NA  Description:...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

BioCardia, Tiger X Medical deal

Cardiovascular company BioCardia will reverse-merge with Tiger X Medical. The combined company will retain BioCardia’s name and will continue development of BioCardia’s CardiAMP cell therapy system, which is in Phase II trials to treat heart...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Financial News

BioCardia withdraws IPO

BioCardia Inc. , San Carlos, Calif.   Business: Cardiovascular, Gene/Cell therapy   Date announced: 2016-04-15   Type: IPO   Underwriters: Cantor Fitzgerald; Roth Capital Partners; Maxim Group   Note: BioCardia withdrew its IPO on NASDAQ,...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

Fundamental reset

Steve Edelson, Senior Editor   After three months of carnage, buysiders acknowledge their conservative prediction of biotech keeping pace with the broader markets is unlikely to occur this year. Instead, investors are looking for the...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Curbed enthusiasm

Following three years of investor exuberance manifested in gains of at least 115% in biotech indices, buysiders say a good 2016 would see biotech merely keeping pace with the broader markets. Nobody is calling an...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Volatile, not futile

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Financial News

BioCardia amends IPO

BioCardia Inc. , San Carlos, Calif.   Business: Cardiovascular, Gene/Cell therapy   Date announced: 2015-07-06   Type: IPO   To be raised: Up to $53.8 million   Shares: 3.8 million   Price: $12-$14   Underwriters:...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Tiers, some fears

3Q15 Financial Markets Preview With biotech more than six years into a bull run, most of the sector's bankers and buysiders remain comfortable in uncharted waters because generalists are not jumping ship en masse in...